Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose modified-release morphine for chronic breathlessness: randomized placebo-controlled trial
2019-002479-33Phase 3Unknown
- Sponsor
- Hull University Teaching Hospitals
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF), airway morbidity and Dyspnoea (SOB) comparing Low-dose modified-release morphine with Placebo (2 arms). Primary endpoint: Worst breathlessness at Day 28. Status: unknown.
02
Drugs
morphine
03
Conditions
heart failure (HF)airway morbidityDyspnoea (SOB)
Beyond the preview
Go deeper on 2019-002479-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002479-33.